Login / Signup

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.

Hiroshi KobayashiShintaro IwataToru WakamatsuKeiko HayakawaTsukasa YonemotoJunji WasaHiroyuki OkaTakafumi UedaSakae Tanaka
Published in: Cancer (2019)
Initial trabectedin at 1.2 mg/m2 has clinically meaningful benefits for patients with L-sarcoma and certain histological subtypes of TRS.
Keyphrases
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • palliative care
  • multiple myeloma
  • hodgkin lymphoma
  • diffuse large b cell lymphoma
  • locally advanced
  • liver metastases
  • squamous cell carcinoma
  • radiation therapy